|
Number
|
Gender
|
Age
|
Location
|
Size (mm)
|
cStage
|
RT (gray/fraction)
|
CT
|
Adverse events (CTCAE v4.0)
|
SCC Ag before CRT
|
SCC Ag after CRT
|
Operation
|
Response
|
Prognosis
|
|---|
|
1
|
F
|
54
|
Rb
|
21.5
|
III B
|
59.4/33
|
S-1 alone
|
None
|
9.3
|
0.9
|
-
|
CR
|
Disease-free for 3 years 8 months
|
|
2
|
F
|
84
|
Rb
|
42.6
|
II A
|
59.4/33
|
S-1 alone
|
None
|
6.8
|
0.9
|
-
|
CR
|
Disease-free for 2 years 1 month
|
|
3
|
F
|
62
|
Rb-a
|
44.4
|
III C
|
45/25
|
S-1 alone
|
Hemorrhage (G-3)
|
54.3
|
1.2
|
PPE
|
pCR
|
Bone and liver metastasis at 1 year 2 months
|
|
Rb
|
125
|
- RT, radiation therapy; CT, chemotherapy; CTCAE, common terminology criteria for adverse events; SCC Ag, squamous cell carcinoma antigen; CRT, chemoradiation therapy; Ra, rectum above the peritoneal reflection; Rb, rectum below the peritoneal reflection; CR, complete response; PPE, posterior pelvic exenteration; pCR, pathological complete response.
